AN2 Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $219.2M
- Price
- $5.81
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.35%
- Volume
- 225.4K
About
AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.
Quick stats
Shares outstanding37.7M
Computed float25.1M
Float / shares66.5%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001880438
AI Summary
AI-generated1/14
minorbullishearnings
AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights
AN2 Therapeutics reported a Q2 net loss of $8.2 million, widening from a $6.5 million loss in the prior year, driven by increased R&D spending as it advances its pipeline.
The company ended the quarter with $79.9 million in cash and investments, projecting a runway into 2029 under its current operating plan.
Operationally, AN2 is advancing three Phase 2 programs: expanding a global PV trial for epetraborole, ongoing enrollment in an M. abscessus study, and preparing for a late-2026 initiation of a Chagas disease trial for AN2-502998.
Red flags
- Net loss widened to $8.2 million from $6.5 million year-over-year